Journal of Thrombosis and Thrombolysis

Article	Citations
Neutrophil extracellular traps and thrombosis in COVID-19	188
Thrombotic complications in 2928 patients with COVID-19 treated in intensive care: a systematic review	64
Delayed catastrophic thrombotic events in young and asymptomatic post COVID-19 patients	54
Thromboembolic prevention and anticoagulant therapy during the COVID-19 pandemic: updated clinical guidance from the anticoagulation forum	42
Prescribing trends of oral anticoagulants in England over the last decade: a focus on new and old drugs and adverse events reporting	41
Incidence of Venous Thromboembolism and Mortality in Patients with Initial Presentation of COVID-19	40
Incidence of thrombotic complications in COVID-19	40
Comparative effectiveness of direct oral anticoagulants and warfarin for the treatment of left ventricular thrombus	40
Autonomic dysfunction in SARS-COV-2 infection acute and long-term implications COVID-19 editor’s page series	38
Pulmonary thrombosis in Covid-19: before, during and after hospital admission	36
Major bleeding complications in critically ill patients with COVID-19 pneumonia	32
Use of antiplatelet drugs and the risk of mortality in patients with COVID-19: a meta‐analysis	31
SARS-CoV-2 infection and thrombotic complications: a narrative review	29
COVID-19 and its sequelae: a platform for optimal patient care, discovery and training	28
Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage	28
Serotonin: a platelet hormone modulating cardiovascular disease	27
Cardiovascular disease and its management in children and adults undergoing hematopoietic stem cell transplantation	27
A comprehensive review of vascular complications in COVID-19	26
Thrombosis in VEXAS syndrome	25
Cellular and molecular mechanisms in COVID-19 coagulopathy: role of inflammation and endotheliopathy	25
External validation of the IMPROVE-DD risk assessment model for venous thromboembolism among inpatients with COVID-19	23
Von Willebrand factor and ADAMTS13 activity as clinical severity markers in patients with COVID-19	22
A systematic review of vaccine-induced thrombotic thrombocytopenia in individuals who received COVID-19 adenoviral-vector-based vaccines	21
Harmonized D-dimer levels upon admission for prognosis of COVID-19 severity: Results from a Spanish multicenter registry (BIOCOVID-Spain study)	21
Blood coagulation factor X: molecular biology, inherited disease, and engineered therapeutics	20

Arterial and venous involvement in Behçet’s syndrome: a narrative review	19
Evidence of systemic endothelial injury and microthrombosis in hospitalized COVID-19 patients at different stages of the disease	19
Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?	18
Efficacy and safety of heparin full-dose anticoagulation in hospitalized non-critically ill COVID-19 patients: a meta-analysis of multicenter randomized controlled trials	18
Lupus anticoagulant and mortality in patients hospitalized for COVID-19	18
Clinical features of patients with acute coronary syndrome during the COVID-19 pandemic	18
Thromboembolic complications of recreational nitrous oxide (ab)use: a systematic review	18
Safety and efficacy of direct oral anticoagulants across body mass index groups in patients with venous thromboembolism: a retrospective cohort design	17
CHA2DS2-VASc score and modified CHA2DS2-VASc score can predict mortality and intensive care unit hospitalization in COVID-19 patients	17
Procoagulant microparticles: a possible link between vaccine-induced immune thrombocytopenia (VITT) and cerebral sinus venous thrombosis	17
Long-term outcomes in acute coronary syndrome patients without standard modifiable risk factors: a multi-ethnic retrospective cohort study Of 5400 asian patients	16
Roles of factor Xa beyond coagulation	16
Clinical outcome with different doses of low-molecular-weight heparin in patients hospitalized for COVID-19	16
Catheter directed compared to systemically delivered thrombolysis for pulmonary embolism: a systematic review and meta-analysis	16
Direct oral anticoagulants versus warfarin in patients with single or double antibody-positive antiphospholipid syndrome	16
Association between vitamin D deficiency and serum Homocysteine levels and its relationship with coronary artery disease	16
Efficacy outcomes and safety measures of intravenous tirofiban or eptifibatide for patients with acute ischemic stroke: a systematic review and meta-analysis of prospective studies	15
Impact of pre-admission antithrombotic therapy on disease severity and mortality in patients hospitalized for COVID-19	14
ST-segment elevation in patients with COVID-19: a systematic review	14
COVID 19 infection associated with thrombotic thrombocytopenic purpura	14
Metformin use in patients hospitalized with COVID-19: lower inflammation, oxidative stress, and thrombotic risk markers and better clinical outcomes	14
Tissue factor: a neglected role in cancer biology	14
Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: evidence of inadequate therapy in a predominantly minority population	14
Association of ABO blood group type with cardiovascular events in COVID-19	14
A case of thrombotic thrombocytopenic purpura associated with COVID-19	14
One-year outcomes of patients with ST-segment elevation myocardial infarction during the COVID-19 pandemic	14
Global coagulation assays in hypercoagulable states	14
Association of chronic anticoagulant and antiplatelet use on disease severity in SARS-COV-2 infected patients	13
Safety of direct oral anticoagulants in patients with mild to moderate cirrhosis: a systematic review and meta-analysis	13
Prior use of anticoagulation is associated with a better survival in COVID-19	13
HIT in the head: a systematic review of cerebral venous sinus thrombosis in classical and autoimmune heparin-induced thrombocytopenia	13
Risk factors for left atrial thrombus or spontaneous echo contrast in non-valvular atrial fibrillation patients with low CHA2DS2-VASc score	13
Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors	13
Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor	13
Outpatient management of chronic warfarin therapy at a pharmacist-run anticoagulation clinic during the COVID-19 pandemic	12
Immature platelets in patients with Covid-19: association with disease severity	12
Comparison of biodegradable and newer generation durable polymer drug-eluting stents with short-term dual antiplatelet therapy: a systematic review and Bayesian network meta-analysis of randomized tri	12
Early platelet dysfunction in patients receiving extracorporeal membrane oxygenation is associated with mortality	12
LncRNA LSINCT5/miR-222 regulates myocardial ischemia‑reperfusion injury through PI3K/AKT pathway	12
Incidence of venous thromboembolism among patients with severe COVID-19 requiring mechanical ventilation compared to other causes of respiratory failure: a prospective cohort study	12
Neurological manifestations of thrombotic microangiopathy syndromes in adult patients	12
Association of serum uric acid with mortality and cardiovascular outcomes in patients with hypertension: a meta-analysis	12
COVID-19 and biomarkers of thrombosis: focus on von Willebrand factor and extracellular vesicles	11
Global haemostatic tests demonstrate the absence of parameters of hypercoagulability in non-hypoxic mild COVID-19 patients: a prospective matched study	11
Combining lung ultrasound and Wells score for diagnosing pulmonary embolism in critically ill COVID-19 patients	11
Working smarter, not harder: evaluating a population health approach to anticoagulation therapy management	11
COVID-19 patient plasma demonstrates resistance to tPA-induced fibrinolysis as measured by thromboelastography	11
Extracellular matrix collagen biomarkers levels in patients with chronic thromboembolic pulmonary hypertension	11
Impact of the pandemic of COVID-19 on emergency attendance for stroke and acute myocardial infarction in Beijing, China	11
Direct oral anticoagulant plasma levels in hospitalized COVID-19 patients treated with dexamethasone	11

Circ_0003204 knockdown protects endothelial cells against oxidized low-density lipoprotein-induced injuries by targeting the miR-491-5p-ICAM1 pathway	11
Performance of the academic research consortium high-bleeding risk criteria in patients undergoing PCI for acute myocardial infarction	11
Anticoagulant treatment satisfaction with warfarin and direct oral anticoagulants for venous thromboembolism	11
Aqueous extract of Whitmania pigra Whitman ameliorates ferric chloride-induced venous thrombosis in rats via antioxidation	11
Incidence and patient characteristics of venous thromboembolism during neoadjuvant chemotherapy for ovarian cancer	11
Evaluation of safety and efficacy outcomes of direct oral anticoagulants versus warfarin in normal and extreme body weights for the treatment of atrial fibrillation or venous thromboembolism	11
LncRNA BANCR induced vascular smooth muscle cell proliferation by downregulating miR-34c methylation in atherosclerosis	10
Current use of rivaroxaban in elderly patients with venous thromboembolism (VTE)	10
Successful outcome with eculizumab treatment in a patient with antiphospholipid syndrome presenting with an unusual thrombotic storm	10
Biomarkers associated with coronary high-risk plaques	10
Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?	10
Inflammatory cytokines enhance procoagulant activity of platelets and endothelial cells through phosphatidylserine exposure in patients with essential hypertension	10
Risk of major bleeding associated with concomitant use of anticancer drugs and direct oral anticoagulant in patients with cancer and atrial fibrillation	10
Impact of COVID-19 outbreak on patients with ST-segment elevation myocardial ınfarction (STEMI) in Turkey: results from TURSER study (TURKISH St-segment elevation myocardial ınfarction registry)	10
Heparin-induced thrombocytopenia in extra-corporeal membrane oxygenation: epidemiology, outcomes, and diagnostic challenges	10
Global coagulation assays in healthy controls: are there compensatory mechanisms within the coagulation system?	10
Causal effect of renal function on venous thromboembolism: a two-sample Mendelian randomization investigation	10
MicroRNA-342-3p loaded by human umbilical cord mesenchymal stem cells-derived exosomes attenuates deep vein thrombosis by downregulating EDNRA	9
Thrombotic and bleeding events, mortality, and anticoagulant use among 546,656 hospitalized patients with COVID-19 in the United States: a retrospective cohort study	9
Downregulating LncRNA XIST attenuated contrast-induced nephropathy injury via regulating miR-133a-3p/NLRP3 axis	9
Predicting mortality, thrombus recurrence and persistence in patients with post-acute myocardial infarction left ventricular thrombus	9
The characteristics and outcomes of critically Ill patients with COVID-19 who received systemic thrombolysis for presumed pulmonary embolism: an observational study	9
An abbreviated Caprini model for VTE risk assessment in trauma	9
International COVID-19 thrombosis biomarkers colloquium: COVID-19 diagnostic tests	9
The risk of venous thromboembolism and physical activity level, especially high level: a systematic review	9
Gender differences with short-term vs 12 months dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-years follow-up results of the REDUCE tr	9
Overexpression of miR-1298 attenuates myocardial ischemia–reperfusion injury by targeting PP2A	9
Lipoprotein(a) levels and risk of adverse events after myocardial infarction in patients with and without diabetes	9
The role of lipoprotein(a) in coronavirus disease 2019 (COVID-19) with relation to development of severe acute kidney injury	9
MicroRNA-29b reduces myocardial ischemia–reperfusion injury in rats via down-regulating PTEN and activating the Akt/eNOS signaling pathway	9
Development and validation of an analytical method for the determination of direct oral anticoagulants (DOAC) and the direct thrombin-inhibitor argatroban by HPLC–MS/MS	9
Elderly people are inherently sensitive to the pharmacological activity of rivaroxaban: implications for DOAC prescribing	9
Direct oral anticoagulants in chronic thromboembolic pulmonary hypertension	8
Efficacy and safety of rivaroxaban in cerebral venous thrombosis: insights from a prospective cohort study	8
Ventilation/perfusion (V/Q) scanning in contemporary patients with pulmonary embolism: utilization rates and predictors of use in a multinational study	8
Comparison of high- and low-dose 4-factor prothrombin complex concentrate for the emergent reversal of oral Factor Xa inhibitors	8
Popliteal cysts are not a risk factor for lower extremity deep vein thrombosis	8
Thromboembolism after treatment with 4-factor prothrombin complex concentrate or plasma for warfarin-related bleeding	8
A modified Khorana score as a risk assessment tool for predicting venous thromboembolism in newly diagnosed advanced lung cancer	8
Plasma levels of extracellular vesicles and the risk of post-operative pulmonary embolism in patients with primary brain tumors: a prospective study	8
Use of direct oral anticoagulants in chronic thromboembolic pulmonary hypertension: a systematic review	8
Screening for venous thromboembolism in patients with COVID-19	8
Neutrophil activation and circulating neutrophil extracellular traps are increased in venous thromboembolism patients for at least one year after the clinical event	8
Trends in management and outcomes of pulmonary embolism with a multidisciplinary response team	8
Intravenous thrombolysis and endovascular thrombectomy for acute ischaemic stroke in patients with Moyamoya disease - a systematic review and meta-summary of case reports	7
Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans	7
Routine screening for pulmonary embolism in COVID-19 patients at the emergency department: impact of D-dimer testing followed by CTPA	7
Cangrelor in addition to standard therapy reduces cardiac damage and inflammatory markers in patients with ST-segment elevation myocardial infarction	7
Antithrombosis stewardship efforts to de-escalate inappropriate combined therapy in outpatient clinics	7
Abnormal immunothrombosis and lupus anticoagulant in a catastrophic COVID-19 recalling Asherson’s syndrome	7
Can a modified-simplified pulmonary embolism severity index (m-sPESI) be used to predict the need for intensive care in hospitalized COVID-19 patients?	7
The allergic myocardial infarction dilemma: is it the anaphylaxis or the epinephrine?	7
Outcomes of a multi-ethnic Asian population on combined treatment with clopidogrel and omeprazole in 12,440 patients	7
Association between previous anticoagulant use and mortality among hospitalized patients with COVID-19	7
Complement system component dysregulation is a distinctive feature of COVID-19 disease: a prospective and comparative analysis of patients admitted to the emergency department for suspected COVID-19 d	7
Pulmonary venous thrombosis in a patient with COVID-19 infection	7
Thrombotic superior vena cava syndrome: a national emergency department database study	7
Edoxaban, a direct oral factor Xa inhibitor, ameliorates coagulation, microvascular thrombus formation, and acute liver injury in a lipopolysaccharide-induced coagulopathy model in rats	7
Switching between direct oral anticoagulants: a systematic review and meta-analysis	7
Prothrombin complex concentrate in major bleeding associated with DOACs; an updated systematic review and meta-analysis	7
Andexanet alfa after 4-factor PCC administration for intracranial hemorrhage: a case series	7
Relations between left atrial appendage contrast retention and thromboembolic risk in patients with atrial fibrillation	7
Short-term non-vitamin K antagonist oral anticoagulants vs. warfarin in preventing device-related thrombosis after left atrial appendage closure	7
Clinical outcomes of surgical embolectomy versus catheter-directed thrombolysis for acute limb ischemia: a nationwide cohort study	6
Effectiveness and safety of oral anticoagulants in non-valvular atrial fibrillation patients with prior bleeding events: a retrospective analysis of administrative claims databases	6
Relationship of health literacy and adherence to oral anticoagulation therapy in patients with atrial fibrillation: a cross‐sectional study	6
SUPPORT‐AF III: supporting use of AC through provider prompting about oral anticoagulation therapy for AF	6
Evaluation of the use of direct oral anticoagulants for the management of heparin-induced thrombocytopenia	6
Impact of a pharmacist driven anticoagulation reversal program at a large academic medical center	6
Systemic bevacizumab as salvage therapy for persistent severe bleeding and anemia in heyde syndrome following aortic valve replacement	6
Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study	6
Patients with autoimmune chronic inflammatory diseases present increased biomarkers of thromboinflammation and endothelial dysfunction in the absence of flares and cardiovascular comorbidities	6
Potential antiviral properties of antiplatelet agents against SARS-CoV-2 infection: an in silico perspective	6
Evaluation of outcomes with apixaban use for venous thromboembolism in hospitalized patients with end-stage renal disease receiving renal replacement therapy	6
A pilot study of procoagulant platelet extracellular vesicles and P-selectin increase during induction treatment in acute lymphoblastic leukaemia paediatric patients: two new biomarkers of thrombogeni	6
Adverse consequences of immediate thrombolysis-related complications: a multi-centre registry-based cohort study of acute stroke	6
Defining platelet response to acetylsalicylic acid: the relation between inhibition of serum thromboxane B2 and agonist-induced platelet aggregation	6
Efficacy and safety of app-based remote warfarin management during COVID-19-related lockdown: a retrospective cohort study	6
Ecchymosis in critical coronavirus disease 2019 (COVID-19) patient in Tangerang, Indonesia: a case report	6
Comparison of 4-factor PCC reversal of apixaban and rivaroxaban versus warfarin for intracranial hemorrhage	6

Use of low-molecular weight heparin, transfusion and mortality in COVID-19 patients not requiring ventilation	6
Ovarian vein thrombosis after coronavirus disease (COVID-19) mimicking acute abdomen: two case reports	6
Management of isolated distal deep–vein thrombosis with direct oral anticoagulants in the RIETE registry	6
Patterns of vascular access device use and thrombosis outcomes in patients with COVID-19: a pilot multi-site study of Michigan hospitals	6
Stroke and presence of patent foramen ovale in sickle cell disease	6
Effects of colchicine on tissue factor in oxLDL-activated T-lymphocytes	6
Association of lipoprotein(a) with intrinsic and on-clopidogrel platelet reactivity	6
Novel multi-marker proteomics in phenotypically matched patients with ST-segment myocardial infarction: association with clinical outcomes	5
Safety of apixaban for venous thromboembolic primary prophylaxis in patients with newly diagnosed malignant glioma	5
Factor Xa inhibitors: critical considerations for clinical development and testing	5
Incidence of venous thromboembolism in patients with non-hematological cancer admitted for COVID-19 at a third-level hospital in Madrid	5
Long-term outcomes of left atrial appendage occlusion in high-risk atrial fibrillation patients: 4-year follow up data	5
The efficacy and safety of direct oral anticoagulants plus aspirin in symptomatic lower extremity peripheral arterial disease: a systematic review and meta-analysis of randomized controlled trials	5
Clinical validation of immunoassay HemosIL® AcuStar HIT-IgG (PF4-H) in the diagnosis of Heparin-induced thrombocytopenia	5
Venous thromboembolism prophylaxis in patients with multiple myeloma: where are we and where are we going?	5
Concomitant factor VIII inhibitor and lupus anticoagulant in an asymptomatic patient	5
The role of β-catenin in pulmonary artery endothelial-mesenchymal transformation in rats with chronic thromboembolic pulmonary hypertension	5
Evaluation of coagulation status using clot waveform analysis in general ward patients with COVID-19	5
Apixaban and rivaroxaban anti-Xa level utilization for guidance of administration of andexanet alfa: a case series	5
Evaluation of a patient specific, targeted-intensity pharmacologic thromboprophylaxis protocol in hospitalized patients with COVID-19	5
Association between plasmatic oxidative stress and thrombosis in primary antiphospholipid syndrome	5
Management of potential drug-drug interactions with nirmatrelvir-ritonavir and oral anticoagulants: a case series	5
Adverse events in patients taking apixaban or rivaroxaban who have undergone bariatric surgery: a retrospective case series	5
Characteristics of carotid atherosclerosis in patients with plaque erosion	5
Different patterns of white matter lesions among patent foramen ovale, atherosclerotic cerebral small vessel disease and cerebral venous thrombosis	5
Prognostic impact of acute kidney injury in patients with acute pulmonary embolism data from the RIETE registry	5
The effect of hydroxychloroquine on platelet activation in model experiments	5
Predicting factors for pulmonary embolism response team activation in a general pulmonary embolism population	5
Single versus multiple and incidental versus symptomatic subsegmental pulmonary embolism: clinical characteristics and outcome	5
Development and validation of a prediction model of catheter-related thrombosis in patients with cancer undergoing chemotherapy based on ultrasonography results and clinical information	5
Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States	4
Massive intraperitoneal hemorrhage in patients with COVID-19: a case series	4
In-hospital prognosis of malignancy-related pulmonary embolism: an analysis of the national inpatient sample 2016–2018	4
Primary pulmonary artery sarcoma versus pulmonary thromboembolism: a multimodal imaging comparison	4
Fibrinspecific liposomes as a potential method of delivery of the thrombolytic preparation streptokinase	4
Double positivity of anti-β2-glycoprotein I domain I and anti-phosphatidylserine/prothrombin antibodies enhances both thrombosis and positivity of anti-ADAMTS13 antibody	4
Effectiveness of a multidisciplinary care program for the management of venous thromboembolism in cancer patients: a pilot study	4
Small lipid core burden index in patients with stable angina pectoris is also associated with microvascular dysfunction: Insights from intracoronary electrocardiogram	4
Different endovascular procedures for stroke with isolated M2-segment MCA occlusion: a real-world experience	4
Towards a personalized selection of antithrombotic agents in patients undergoing PCI: the role of clinical presentation in tools for risk assessment	4
Appropriateness of inpatient dosing of direct oral anticoagulants for atrial fibrillation	4
Pulmonary embolism in patients with COVID-19 pneumonia on adequate oral anticoagulation	4
The long-term survival in patients with chronic thromboembolic pulmonary hypertension: experience from a single center in China	4
Pre-admission antithrombotic use is associated with 3-month mRS score after thrombectomy for acute ischemic stroke	4
ICODE: the international COVID-19 thrombosis biomarkers colloquium—novel soluble biomarkers: circulating cell-free nucleic acids and other molecules	4
The relation between acute intracerebral hemorrhage and diffusion-weighted imaging lesions: a meta-analysis	4
“Lockdown-thrombosis”—an unexpected problem of the COVID-19 pandemic?	4
The first report of a JAK2 V617F-positive myeloproliferative neoplasm with initial manifestation as a rare pampiniform venous plexus thrombosis and review of the literature	4
Eltrombopag for refractory vaccine-induced immune thrombotic thrombocytopenia	4
Impact of antithrombin III and enoxaparin dosage adjustment on prophylactic anti-Xa concentrations in trauma patients at high risk for venous thromboembolism: a randomized pilot trial	4
Platinoid effects on human plasmatic coagulation kinetics: a viscoelastic analysis	4
Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI	4
Venous and arterial thromboembolic disease in COVID-19	4
Prophylactic versus therapeutic anticoagulation for survival of patients with COVID-19 on steroid	4
Metal ion chelation enhances tissue plasminogen activator (tPA)-induced thrombolysis: an in vitro and in vivo study	4
Oseltamivir as rescue therapy for persistent, chronic, or refractory immune thrombocytopenia: a case series and review of the literature	4
Medical publishing during the COVID-19 pandemic: then and now	4
Prescribing of anticoagulation for atrial fibrillation in primary care	4
Conservative treatment vs thrombus removal for Iliofemoral vein thrombosis in patients with congenital abnormalities of the inferior vena cava: a case report and systematic review of the literature	4
Increased risk of venous thromboembolism among patients with familial Mediterranean fever	4
Efficacy of prothrombin complex concentrate in the management of oral factor Xa inhibitors associated major bleed assessed by ISTH and ANNEXA-4 criteria	4
Thromboembolic events following mRNA vaccines for COVID 19: a case series	4
Major hemorrhage and mortality in COVID-19 patients on therapeutic anticoagulation for venous thromboembolism	4
Bleeding risk in patients with venous thromboembolic events treated with new oral anticoagulants	4
Favourable collaterals according to the Careggi Collateral Score grading system in patients treated with thrombectomy for stroke with middle cerebral artery occlusion	4
Impact of thrombus burden on long-term clinical outcomes in patients with either anterior or non-anterior ST-segment elevation myocardial infarction	4
U shape association of hemoglobin level with in-hospital mortality for COVID-19 patients	4
Efficacy of a hypolipid diet in patients with primary antiphospholipid syndrome with dyslipidemia: a prospective study	4
The use of colchicine as an anti-inflammatory agent for stroke prevention in patients with coronary artery disease: a systematic review and meta-analysis	4
Utilization trends and outcomes of catheter-directed thrombolysis for pulmonary embolism in the US by race/ethnicity	4
The safety and efficacy of systemic versus catheter-based therapies: application of a prognostic model by a pulmonary embolism response team	4
Real world prescribing practices of apixaban or rivaroxaban lead-in doses for the treatment of venous thromboembolism in hospitalized patients	4
Association of the careggi collateral score with radiological outcomes after thrombectomy for stroke with an occlusion of the middle cerebral artery	4
Coronary artery aneurysm presenting as acute coronary syndrome: two case reports and a review of the literature	4
Initial assessment of α-synuclein structure in platelets	4
Anticoagulation in patients with atrial fibrillation, thrombocytopenia and hematological malignancy	4